Kidney International Reports最新文献

{"title":"Genetic Kidney Disease Across the Lifespan – Emerging Insights From Clinical Genomics in Older People","authors":"Kathleen Nicholls , Andrew J. Mallett","doi":"10.1016/j.ekir.2025.06.050","DOIUrl":"10.1016/j.ekir.2025.06.050","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2548-2550"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CKD Beyond the Clinic: A Holistic Projection of its Global Burden","authors":"Anne-Laure Faucon","doi":"10.1016/j.ekir.2025.06.031","DOIUrl":"10.1016/j.ekir.2025.06.031","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2524-2526"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Double-Icodextrin Dose Randomized Controlled Trial of a Double Icodextrin Dose for Older Patients on Incremental Continuous Ambulatory Peritoneal Dialysis","authors":"Eric Goffin ,&nbsp;Clémence Béchade ,&nbsp;Cécile Courivaud ,&nbsp;Catherine Bresson ,&nbsp;Françoise Heibel ,&nbsp;Jean-Claude Stoléar ,&nbsp;Karlien François ,&nbsp;Fatouma Touré ,&nbsp;Didier Aguilera ,&nbsp;François Vrtovsnik ,&nbsp;Bert Bammens ,&nbsp;Michel Jadoul ,&nbsp;Olivier Devuyst ,&nbsp;Martin Wilkie ,&nbsp;Aurélie Bertrand ,&nbsp;Thierry Lobbedez","doi":"10.1016/j.ekir.2025.05.036","DOIUrl":"10.1016/j.ekir.2025.05.036","url":null,"abstract":"<div><h3>Introduction</h3><div>Icodextrin enhances ultrafiltration (UF) in patients on peritoneal dialysis (PD) but is restricted to 1 bag/d, according to regulatory authorities. The Double-Icodextrin Dose (DIDo) study is a prospective randomized trial investigating the superiority and safety of using 2 bags/d versus 1 bag/d of icodextrin to extend incremental (3 bags/d) continuous ambulatory PD (CAPD) duration in older incident patients.</div></div><div><h3>Methods</h3><div>After a 2-month “run-in” period, the patients were randomized to 2 icodextrin (“double dose”) + 1 glucose or 1 icodextrin (“single dose”) + 2 glucose dialysates daily. The primary end point was a composite of excessive use of hypertonic dialysates, transfer to another dialysis modality (automated PD [APD], nonincremental CAPD, or hemodialysis) or death at month 9. Secondary end points included mortality, daily UF, technique survival, rates of peritonitis and hospitalizations, and safety at month 18.</div></div><div><h3>Results</h3><div>Forty-one patients were randomized to double dose and 42 to single-dose icodextrin. Baseline characteristics were well-balanced between groups. At month 9, the proportion of patients who discontinued 3 exchanges/d was similar between those receiving the double and the single icodextrin dose (16 [39%] vs. 21 [50%]; HR: 0.69; 95% confidence interval: 0.35–1.33). The results were similar at month 18. Patients in the double dose icodextrin had higher net UF and less hypertonic dialysates use. Rates of peritonitis, hospitalizations, residual urine output decline and serious adverse events (SAEs) were similar between both groups.</div></div><div><h3>Conclusion</h3><div>In older patients on incremental CAPD, the double icodextrin dose did not reduce the primary outcome incidence compared with the single icodextrin dose. Significantly enhanced UF was observed in the double icodextrin dose group and no safety issue was identified.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2585-2596"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Furosemide Use in Advanced CKD: Balancing Risks and Benefits","authors":"Thierry Hannedouche ,&nbsp;Maxime Ingwiller","doi":"10.1016/j.ekir.2025.05.047","DOIUrl":"10.1016/j.ekir.2025.05.047","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Page 2877"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the Letter to the Editor Entitled “Prevalence of Discordant Estimated GFR Among Adults in a Community-Based Population”","authors":"Pierre Delanaye ,&nbsp;Hans Pottel","doi":"10.1016/j.ekir.2025.06.024","DOIUrl":"10.1016/j.ekir.2025.06.024","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2884-2885"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the Letter to the Editor Entitled “Renal Tubular Epithelial Cells as Marker of Tubular Damage in Acute Kidney Disease”","authors":"Leonie Wagner ,&nbsp;Jan Klocke ,&nbsp;Philipp Enghard","doi":"10.1016/j.ekir.2025.06.008","DOIUrl":"10.1016/j.ekir.2025.06.008","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Page 2882"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Outcome of Adult Patients With Membranous Nephropathy Treated With Rituximab","authors":"Maria J. Vargas-Brochero ,&nbsp;Elisabeth Lafaut ,&nbsp;Yeshwanter Radhakrishnan ,&nbsp;Ilario Russo ,&nbsp;Sanjeev Sethi ,&nbsp;Ladan Zand ,&nbsp;Daniela Valencia ,&nbsp;Miriam Machado ,&nbsp;Maria Jose Soler ,&nbsp;Anila Cara ,&nbsp;Gian Marco Berti ,&nbsp;Daniel C. Cattran ,&nbsp;Fernando C. Fervenza","doi":"10.1016/j.ekir.2025.05.013","DOIUrl":"10.1016/j.ekir.2025.05.013","url":null,"abstract":"<div><h3>Introduction</h3><div>Rituximab (RTX) therapy has become the standard of care for treatment of membranous nephropathy (MN). However, data on hard outcomes such as end-stage kidney disease (ESKD) and loss of estimated glomerular filtration rate (eGFR), are lacking.</div></div><div><h3>Methods</h3><div>This was a retrospective study on all patients with MN treated with RTX between January 2000 and December 2022. The primary outcomes were ESKD and eGFR loss &gt; 50%. Clinical outcomes were complete remission (CR), partial remission (PR) (reduction in baseline proteinuria ≥ 50% and proteinuria ≤ 3.5 g/24 h), and immunological remission (IR) (serum antiphospholipase A receptor antibody [PLA2R-Ab] depletion).</div></div><div><h3>Results</h3><div>A total of 159 patients were included (75.5% male, 87.4% White, median age: 58 years); 52.8% had previous immunosuppression (IS). Baseline serum creatinine was 1.50 (1.1–1.9) mg/dl, eGFR was 54.6 (37.4–72.5) ml/min per 1.73 m², proteinuria was 9.2 (6.7–11.9) g/24 h, and serum albumin was 2.7 (2.2–3.2) g/dl; Of the patients, 108 (75.5%) had PLA2R-Ab–associated MN (PLA2R-MN); and 140 of 159 (88.1%) attained CR or PR. Median (interquartile range [IQR]) time to CR and PR were 22.6 (15.5–37.4) and 6.8 (3.6–12.1) months, respectively. Failure to respond to RTX was observed in 11.9% of patients. Previous IS and interstitial fibrosis/tubular atrophy (IFTA) ≥ 25% were independent factors associated with failure to respond to RTX. Patients treated only with RTX with a median follow-up of 62.6 months; 7 of 159 (4.4%) developed ESKD with an estimated renal survival of 97% (95% confidence interval [CI]: 94%–100%) and 95.4% (95% CI: 91.2%–99%) at 5 and 10 years, respectively.</div></div><div><h3>Conclusion</h3><div>RTX treatment is associated with excellent long-term renal survival that compares favorably with historical survival rates using the cyclic corticosteroids/cyclophosphamide regimen.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2630-2641"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing Cystatin C Estimated GFR With Creatinine Estimated GFR in Acute Kidney Injury Recovery","authors":"Kerry L. Horne ,&nbsp;Rebecca Packington ,&nbsp;John Monaghan ,&nbsp;Mary Jo Kurth ,&nbsp;Ciaran Richardson ,&nbsp;Mark W. Ruddock ,&nbsp;Maarten W. Taal ,&nbsp;Rosamonde E. Banks ,&nbsp;Nicholas M. Selby","doi":"10.1016/j.ekir.2025.05.004","DOIUrl":"10.1016/j.ekir.2025.05.004","url":null,"abstract":"<div><h3>Introduction</h3><div>Current guidelines recommend creatinine-based estimated glomerular filtration rate (eGFRcr) to assess kidney recovery after acute kidney injury (AKI); however, this may be inaccurate because of loss of muscle mass. Cystatin C-based eGFR (eGFRcys) is an alternative that is not similarly affected. In addition, simple calculations (e.g., creatinine muscle index, CMI) incorporating the difference between eGFRcr and eGFRcys may indicate prognosis. We sought to determine whether eGFRcr differs from eGFRcys after AKI and whether CMI is associated with mortality.</div></div><div><h3>Methods</h3><div>The AKI Risk in Derby (ARID) study is a prospective parallel-group cohort study. Hospitalized participants with and without exposure to AKI were matched 1:1 for age, baseline kidney function, and diabetes. eGFRcr and eGFRcys at 3 months after admission were compared in 849 participants. Associations between CMI and outcomes, including mortality, heart failure, and hospitalization were assessed at 5 years.</div></div><div><h3>Results</h3><div>eGFRcys was lower than eGFRcr (53.4, [interquartile range, IQR: 34.3–85.5] vs. 68.4 [IQR: 52.5–84.7] ml/min per 1.73 m², <em>P</em> &lt; 0.001), with more pronounced differences in those with AKI. eGFRcys categorized more participants with chronic kidney disease (CKD) (in AKI group: eGFRcr &lt; 60 ml/min per 1.73 m² in 44.9%; eGFRcys &lt; 60 ml/min per 1.73 m² in 69.6%, <em>P</em> &lt; 0.001). In the AKI group, higher CMI was independently associated with lower mortality at 5 years (adjusted hazard ratio: 0.931 [0.874–0.992] mg/d per 1.73 m², <em>P</em> = 0.03).</div></div><div><h3>Conclusion</h3><div>There are significant differences at 3 months after AKI in eGFR derived from creatinine versus cystatin C. The magnitude of difference between these estimates is associated with subsequent mortality. Further research is required to determine the optimal approach to patient assessment after AKI.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2741-2750"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the Letter to the Editor Entitled “Refining Tolvaptan Dosing in ADPKD: The Role of Urinary Biomarkers in Enhancing Outcomes”","authors":"Neera K. Dahl ,&nbsp;Vicente E. Torres","doi":"10.1016/j.ekir.2025.05.040","DOIUrl":"10.1016/j.ekir.2025.05.040","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Page 2880"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal Tubular Epithelial Cells as Marker of Tubular Damage in Acute Kidney Disease","authors":"Matthijs Oyaert ,&nbsp;Sigurd Delanghe ,&nbsp;Joris Delanghe ,&nbsp;Eric Hoste ,&nbsp;Marijn Speeckaert","doi":"10.1016/j.ekir.2025.05.052","DOIUrl":"10.1016/j.ekir.2025.05.052","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Page 2881"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}